MC-150 is under clinical development by Chongqing Precision Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MC-150’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MC-150 overview
MC-1-50 is under development for the treatment of B-cell acute lymphocytic leukemia (ALL) and B- cell non-Hodgkin lymphoma (NHL), diffuse large b-cell lymphoma, chronic lymphocytic leukemia (CLL), follicular lymphoma, mantle cell lymphoma, non-specific type (DLBCL, NOS), chronic inflammatory associated DLBCL, primary cutaneous DLBCL (leg type), EBV-positive DLBCL (NOS); High-grade B-cell lymphomas (including NOS and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements), Primary mediastinal large B-cell lymphoma, Rich T/ histiocytic large B-cell lymphoma; Transformed DLBCL, Grade 3b follicular lymphoma (FL3b). The therapeutic candidate is administered through parenteral and intravenous route and comprises of autologous T-cells genetically engineered to express chimeric antigen receptors (CAR) targeting CD19 expressing cells. It is being developed based on PrimeCAR platform.
For a complete picture of MC-150’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
